In therapeutic indications such as NSCLC, where there is a clear unmet medical need, delayed access to new therapies following regulatory approval is a significant challenge. Nintedanib meets a medical need in NSCLC; however, patients across Europe are not gaining equal access to this new therapy due to varying reimbursement procedures.
from Cancer via ola Kala on Inoreader http://annonc.oxfordjournals.org/cgi/content/short/mdw569v1?rss=1
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου